Tesamorelin vs Tesamorelin + Ipamorelin
A side-by-side research comparison of Tesamorelin and Tesamorelin + Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tesamorelin | Tesamorelin + Ipamorelin |
|---|---|---|
| Full name | Tesamorelin Acetate (Egrifta) | Tesamorelin/Ipamorelin Combination |
| Category | Growth Hormone | Growth Hormone |
| Status | FDA Approved | Compounded combination |
| Mechanism | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. | Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility. |
| Molecular weight | 5,136 Da | Blend |
| Half-life | 26-38 minutes | Tesamorelin: ~26 min; Ipamorelin: ~2 hours. Combined peak GH at 30-60 min post-injection. |
| Bioavailability | High (SubQ) | High (subcutaneous) |
| Typical dose | 2 mg | Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg |
| Frequency | Once daily | Once daily (before bed) or twice daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Tesamorelin + Ipamorelin reported benefits
- Significant fat loss (especially visceral/abdominal)
- Lean muscle gains
- Improved sleep quality
- Enhanced recovery
- Anti-aging effects
- Better body composition without exogenous HGH side effects
Related comparisons
Research and educational reference only. Not medical advice.